Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.
Patel, J.R., Shuai, Q., Dinges, J., Winn, M., Pliushchev, M., Fung, S., Monzon, K., Chiou, W., Wang, J., Pan, L., Wagaw, S., Engstrom, K., Kerdesky, F.A., Longenecker, K., Judge, R., Qin, W., Imade, H.M., Stolarik, D., Beno, D.W., Brune, M., Chovan, L.E., Sham, H.L., Jacobson, P., Link, J.T.(2007) Bioorg Med Chem Lett 17: 750-755
- PubMed: 17110106 
- DOI: https://doi.org/10.1016/j.bmcl.2006.10.074
- Primary Citation of Related Structures:  
2IRW - PubMed Abstract: 
A novel class of adamantane ethers 11beta-hydroxysteroid hydrogenase type I inhibitors has been discovered. These compounds have excellent HSD-1 potency and selectivity against HSD-2. The structure-activity relationships, selectivity, metabolism, PK, ex vivo pharmacodynamic data, and an X-ray crystal structure of one of these inhibitors bound to h-HSD-1 are discussed.
Organizational Affiliation: 
Global Pharmaceutical Research & Development, Abbott Laboratories, R43G, AP52, 200 Abbott Park Road, Abbott Park, IL-60064-6217, USA. jyoti.patel@abbott.com